1. Home
  2. BHVN vs FTRE Comparison

BHVN vs FTRE Comparison

Compare BHVN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biohaven Ltd.

BHVN

Biohaven Ltd.

HOLD

Current Price

$11.39

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$13.37

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHVN
FTRE
Founded
2013
1996
Country
United States
United States
Employees
N/A
14000
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
BHVN
FTRE
Price
$11.39
$13.37
Analyst Decision
Buy
Buy
Analyst Count
14
9
Target Price
$29.08
$14.06
AVG Volume (30 Days)
1.7M
1.5M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
26.08
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.00
52 Week Low
$7.48
$3.97
52 Week High
$18.57
$18.67

Technical Indicators

Market Signals
Indicator
BHVN
FTRE
Relative Strength Index (RSI) 68.12 56.26
Support Level $10.75 $9.01
Resistance Level $11.92 $18.26
Average True Range (ATR) 0.66 0.65
MACD 0.20 -0.24
Stochastic Oscillator 99.48 13.44

Price Performance

Historical Comparison
BHVN
FTRE

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Share on Social Networks: